Oncology Focus Areas:
Our other therapy areas

    • {%buzitemName%}
        {%buzbrandMenuItems%}
    • {%bitemName%} {%barrowSpan%}
        {%bsubBrandMenuItems%}
    • {%sbitemName%} {%sbarrowSpan%}
        {%sbproductMenuItems%}
    • {%pitemKeyName%} {%pitemBadges%} {%parrowSpan%}
      {%pselfProduct%}
    • {%mNavitemName%}
      • {%lScountries%}
    • {%allMenuItem%}
      • {%cSlanguages%}

      • This website is for UK Healthcare Professionals only

      This promotional website is for UK Healthcare Professionals involved in the management of haematological malignancies. Adverse event reporting information can be found below.

      Tepkinly▼ (epcoritamab)

      I

      TEPKINLY PRESCRIBING INFORMATION [External link]
      SUMMARY OF PRODUCT CHARACTERISTICS
      PATIENT CARD

      Tepkinly is licensed
      for 3L+ DLBCL

      Tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B‑cell lymphoma (DLBCL) after two or more lines of systemic therapy.1

      Tepkinly has a conditional marketing authorisation
      - further data awaited.

      You are advised to read the Prescribing Information and Summary of Product Characteristics, accessible via the links above, to evaluate patient suitability for Tepkinly.

      Adverse event reporting information can be found at the bottom of this page.

      Tepkinly is licensed for 3L+ DLBCL

      Tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B‑cell lymphoma (DLBCL) after two or more lines of systemic therapy.1

      Tepkinly has a conditional marketing authorisation
      - further data awaited.

      You are advised to read the Prescribing Information and Summary of Product Characteristics, accessible via the links above, to evaluate patient suitability for Tepkinly.

      Adverse event reporting information can be found at the bottom of this page.

      UK-EPCOR-240219 | June 2024

      Welcome to AbbVie Pro for Tepkinly in 3L+ DLBCL

      divider 2

      Discover how Tepkinly could be a treatment option for your patients with 3L+ DLBCL by exploring the data and practical resources provided.

      blue button tepkinly

      Tepkinly is the first and only licensed subcutaneous bispecific antibody for 3L+ DLBCL1

      NICE BUTTON

      Recommendations include:

      Tepkinly is recommended as an option for treating relapsed or refractory DLBCL
      in adults after 2 or more systemic treatments in adults, only if they have
      previously had polatuzumab vedotin or it is contraindicated or not tolerated.

      Tepkinly is only recommended if the company provides it
      according to the commercial arrangement.
       

      Click here to access the full guidance on the NICE website

      This button links to an external website which is not under the control of AbbVie.
      AbbVie is not responsible for the content on this site or any further links from the site.

      NICE publishes recommendations for
      Tepkinly in 3L+ DLBCL2

      Recommendations include:

      Tepkinly is recommended as an option for treating relapsed or refractory DLBCL in adults after 2 or more systemic treatments in adults, only if they have previously had polatuzumab vedotin or it is contraindicated or not tolerated.

      Tepkinly is only recommended if the company provides it according to the commercial arrangement.

      Click here to access the full guidance on the NICE website

      This button links to an external website which is not under the control of AbbVie.
      AbbVie is not responsible for the content on this site or any further links from the site.

      button tepkinly v4

      Indication under review: as monotherapy for the treatment of adult patients
      with relapsed or refractory DLBCL after two or more lines of systemic therapy.
       

      Click here to access the full advice on the SMC website

      This button links to an external website which is not under the control of AbbVie.
      AbbVie is not responsible for the content on this site or any further links from the site.

      SMC accepts Tepkinly for use within NHSScotland as an option for 3L+ DLBCL3

      Indication under review: as monotherapy for the treatment of adult patients with relapsed or refractory DLBCL after two or more lines of systemic therapy.

      Click here to access the full advice on the SMC website

      This button links to an external website which is not under the control of AbbVie.
      AbbVie is not responsible for the content on this site or any further links from the site.

      Tepkinly is a subcutaneous T-cell engaging CD3xCD20 bispecific antibody1,4,5

      divider 2

      Tepkinly is a humanised IgG-1 bispecific antibody that binds to a specific extracellular epitope of CD20 on B cells and to CD3 on T cells1

      By simultaneously binding CD20-expressing B cells and CD3-expressing T cells, Tepkinly induces specific T-cell activation and T-cell-mediated killing of the CD20-expressing cancer cells1

      image and text
      image and text

      Tepkinly's Fc region is silenced for direct immune effector mechanisms1

      purple box 3 v2

      In preclinical studies, Tepkinly demonstrated T-cell-mediated lysis of CD20-expressing cells5

      Downloadable resource

      banner
      DADownload

      Tepkinly dosing and administration guide

      A digital guide to optimal dosing and administration of Tepkinly. The guide also provides instructions on how to prepare and store Tepkinly correctly, along with important safety information.

      Abbreviations

      3L+=third line plus; BsAb=bispecific antibody; CD3=cluster of differentiation 3; CD20=cluster of differentiation 20; DLBCL=diffuse large B-cell lymphoma; Fc region=fragment crystallization region; IgG-1=Immunoglobulin G1; NICE=National Institute for Health and Care Excellence; SMC=Scottish Medicines Consortium.

      References

      1. Tepkinly Summary of Product Characteristics. 
      2. NICE 2024. Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments. Available at https://www.nice.org.uk/guidance/ta954 (Accessed: December 2024).
      3. Scottish Medicines Consortium Documents SMC2632. Available at: https://scottishmedicines.org.uk/medicines-advice/epcoritamab-tepkinly-smc2632-full/ (Accessed: December 2024).
      4. Thieblemont C et al. J Clin Oncol. 2022; 41(12): 2238-47.
      5. Engelberts P et al. EBioMedicine. 2020; 52: 102625.

      References

      1. Tepkinly Summary of Product Characteristics. 
      2. NICE 2024. Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments. Available at https://www.nice.org.uk /guidance/ta954 (Accessed: December 2024).
      3. Scottish Medicines Consortium Documents SMC2632. Available at: https://scottishmedicines.org.uk /medicines-advice/epcoritamab-tepkinly-smc2632-full/ (Accessed: December 2024).
      4. Thieblemont C et al. J Clin Oncol. 2022; 41(12): 2238-47.
      5. Engelberts P et al. EBioMedicine. 2020; 52: 102625.
      TEPKINLY PRESCRIBING INFORMATION

      By clicking the link above, you will leave the AbbVie Pro website and be taken to the eMC PI portal website.

      UK-EPCOR-240398. Date of preparation: December 2024.

      Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.

      Adverse events should also be reported to AbbVie on GBPV@abbvie.com

      Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores. Adverse events should also be reported to AbbVie on GBPV@abbvie.com

       

      This website is for UK Healthcare Professionals only

      UK-ABBV-230225. Date of preparation June 2023. This website has been developed and funded by AbbVie Ltd.

      © 2023 AbbVie Ltd. All rights reserved. Registered Number: 08004972 England.